Answers are grounded in this paper and cite their sources.
Summary Based on pre-therapy whole-body 131I scintiscans showing only residual thyroid, 64 patients with differentiated thyroid cancer were treated with 1100 MBq (< 30 mCi) 131I as out-patients. A follow-up whole-body scan with uptake measurements was made 6–12 months later. An uptake of ≤ 0.3% and a scan showing no abnormal uptake outside of the region of the thyroid bed was accepted as a successful outcome. Four patients were subsequently excluded, three of whom had no repeat uptakes and one developed a local recurrence before the repeat 131I scan could be completed. When uptake of 131I before treatment was restricted to the region of the thyroid and the percentage retained was ≤ 10%, the probability of successful ablation was 92%. When the uptake was < 10%, this fell to 59%. A serum TSH < 10 μU ml-1 at the time of the first scan was associated with ablation (i.e. an uptake of ≤ 0.3% on the follow-up scan) in 93% of patients. We recommend measurement of TSH and a whole-body scan to exclude regional or distant metastases, plus calculation of uptake in the neck to determine whether out-patient therapy with 1100 MBq is appropriate.
No takes yet. Share an insight, caveat, or question.
WYNGAARDEN et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: